Eligibility for Cardiovascular Risk Reduction Therapy in the U.S. Based on SELECT Trial Criteria: Insights from the National Health and Nutrition Examination Survey

By sjmartinez • November 12, 2023

Lu Y, Liu Y, Jastreboff AM, Khera R, Ndumele CD, Rodriguez F, Watson KE, Krumholz HM. Eligibility for Cardiovascular Risk Reduction Therapy in the U.S. Based on SELECT Trial Criteria: Insights from the National Health and Nutrition Examination Survey. Circ Cardiovasc Qual Outcomes. 2023 Nov 11. doi: 10.1161/CIRCOUTCOMES.123.010640. Epub ahead of print. PMID: 37950677.

Tags: Cardiology/Epi, Publications

Bioelectronic block of stellate ganglia mitigates pacing-induced heterogeneous release of catecholamine and neuropeptide Y in the infarcted pig heart

Vrabec T, Bender S, Chan SA, Cha S, Haridas S, Hanna P, Ajijola OA, Shivkumar K, Smith C, Ardell JL. Bioelectronic block of stellate ganglia[...]

Atrial Arrhythmias After PFO Device Closure: Common, Clinically Important, and Preventable

Tobis JM, Carroll JD. Atrial Arrhythmias After PFO Device Closure: Common, Clinically Important, and Preventable? Circulation. 2024 Nov 19;150(21):1669-1670. doi: 10.1161/CIRCULATIONAHA.124.071851. Epub 2024 Nov 18.[...]

Early Adoption of Sodium-Glucose Cotransporter-2 Inhibitor in Patients Hospitalized With Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Abdel Jawad M, Spertus JA, Ikeaba U, Greene SJ, Fonarow GC, Chiswell K, Chan PS. Early Adoption of Sodium-Glucose Cotransporter-2 Inhibitor in Patients Hospitalized With[...]